https://scholars.lib.ntu.edu.tw/handle/123456789/537045
標題: | Inadequate humoral immunogenicity to recombinant hepatitis B virus vaccine in biliary atresia children | 作者: | JIA-FENG WU YEN-HSUAN NI HUEY-LING CHEN HONG-YUAN HSU HONG-SHIEE LAI MEI-HWEI CHANG |
公開日期: | 2008 | 卷: | 64 | 期: | 1 | 起(迄)頁: | 100-104 | 來源出版物: | Pediatric Research | 摘要: | This study aimed to investigate the primary immunogenicity and the long-term efficacy of recombinant hepatitis B virus (HBV) vaccine in biliary atresia (BA) children. Fifty BA infants (age, 11 ± 3.9 mo), and 23 BA patients at childhood (age, 8.5 ± 0.22 y) were included for the evaluation of HBV surface antibody (anti-HBs) levels after three doses of recombinant HBV vaccine immunization. Age- and gender-matched healthy infants (n = 50) and children (n = 23) were enrolled as the control group. Serum samples of the study populations were collected for HBV seromarkers determination. In the absence of hepatitis B virus core antibody and HBV surface antigen, serum anti-HBs level above 10 IU/L was considered adequate immunogenicity to HBV vaccine. The prevalence of adequate anti-HBs levels after recombinant HBV vaccine in BA infants was significantly lower than those of the controls (p = 0.006). There was no difference in the prevalence between childhood BA patients and their matched controls (p = 0.538). In conclusion, adequate primary humoral immunity after the standard doses of recombinant HBV vaccine in BA infants is hard to establish. However, once immunity is acquired, BA children have adequate anti-HBs titer in the long run. Copyright ? 2008 International Pediatric Research Foundation, Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-49849105003&doi=10.1203%2fPDR.0b013e3181732908&partnerID=40&md5=f201c77856952257975ed547c1d55fcd https://scholars.lib.ntu.edu.tw/handle/123456789/537045 |
ISSN: | 0031-3998 | DOI: | 10.1203/PDR.0b013e3181732908 | SDG/關鍵字: | hepatitis B antibody; hepatitis B vaccine; membrane antigen; hepatitis B antibody; hepatitis B vaccine; recombinant vaccine; article; bile duct atresia; child; childhood; clinical evaluation; control group; controlled study; drug efficacy; female; hepatitis B; Hepatitis B virus; human; humoral immunity; immunization; immunogenicity; infant; major clinical study; male; population; preschool child; prevalence; priority journal; school child; serology; virus core; antibody production; bile duct atresia; blood; case control study; cross-sectional study; immunology; nutritional status; time; Antibody Formation; Biliary Atresia; Case-Control Studies; Child; Cross-Sectional Studies; Female; Hepatitis B Antibodies; Hepatitis B Vaccines; Humans; Immunization Schedule; Infant; Male; Nutritional Status; Time Factors; Vaccines, Synthetic |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。